

Special Issue

Advances in Photodynamic Therapy for Cancer

Message from the Guest Editor

According to the World Health Organization (WHO), cancer is the second leading cause of death in the world, responsible for 9.5 million deaths in 2020. This number is estimated to increase to 13.2 million deaths in 2030. The incidence of cancer varies depending on the region of the world. Low-income countries have lower incidence rates, but they also have higher mortality rates. Photodynamic therapy (PDT) is emerging as a revolutionary weapon in the fight against cancer. This Special Issue delves into the cutting-edge advancements in PDT, showcasing its potential to transform cancer treatment. PDT has the potential to become a more effective and less toxic treatment for cancer. As research continues, PDT may become a more widely available treatment option for cancer patients. PDT has the potential to significantly increase cure rates and improve the quality of life of cancer patients. In this Special Issue, we aim to draw together research from experts in the field that highlight therapeutic agents and strategies in PDT and identify future directions that will lead to discoveries and therapies for cancer.

Guest Editor

Prof. Dr. Cristina Pacheco-Soares

Laboratory of Cell Compartment Dynamics, Institute of Research and Development, University of Vale do Para ba, S o Jos  dos Campos, Brazil

Deadline for manuscript submissions

closed (30 July 2024)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/193795

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)